Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-23T07:41:10.790Z Has data issue: false hasContentIssue false
  • English
  • Français

Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: A systematic review

Published online by Cambridge University Press:  15 April 2020

H. Caisley  and
U. Müller
H. Caisley
Affiliation:
Adult Attention Deficit Hyperactivity Disorder (ADHD) Research Clinic, Cambridge, UK Hinchingbrooke Healthcare NHS Trust, Huntingdon, Cambridgeshire, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
U. Müller*
Affiliation:
Adult Attention Deficit Hyperactivity Disorder (ADHD) Research Clinic, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK Department of Psychiatry, University of Cambridge, Box 189, Level E4, Addenbrooke's Hospital, Hills Road, Cambridge, UK
*
*Corresponding author. E-mail address: [email protected] (U. Müller).
Get access

Abstract

Adherence to a regular medication regimen may be challenging for adults with attention deficit hyperactivity disorder (ADHD). Some report taking psychostimulants on a pro re nata (PRN) basis. This review aims to establish the rate of adherence, and reasons for and consequences of non-adherence to medication for ADHD in adults, and to review literature on PRN dosing of psychostimulants in these patients. A systematic literature search was conducted. Four primary research studies have investigated the rate of adherence to medication in adults with ADHD. Mean adherence rate in two studies ranged from 52% to 87%. A number of possible reasons for poor adherence have been suggested. Prospective studies are needed to further define the rate of adherence and causes of poor adherence. Evidence examining whether differences in adherence affect clinical outcomes is equivocal. Therefore, caution should be applied to the assumption that maximising adherence to regular medication regimens will improve clinical outcomes. Two articles acknowledge that patients take medication on a PRN basis. Studies comparing the effectiveness of a regular and PRN regimen of psychostimulants are needed. If PRN dosing is as effective as a regular regimen, advantages might include enhanced doctor-patient communication, reduced side effects and cost savings.

Keywords

Attention deficit hyperactivity disorderAdultsAdherencePro re nataMethylphenidateAmphetamine
Type
Review
Information
European Psychiatry , Volume 27 , Issue 5 , July 2012 , pp. 343 - 349
Copyright
Copyright © Elsevier Masson SAS 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adler, L., Nierenberg, A.Review of medication adherence in children and adults with ADHD. Postgrad Med. 122 1: 2010 184–191.10.3810/pgm.2010.01.2112CrossRefGoogle ScholarPubMed
American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders (4th edition text revision). Washington (DC): APA; 2000.Google Scholar
Barkley, R.Global issues related to the impact of untreated attention deficit/hyperactivity disorder from childhood to young adulthood. Postgrad Med. 120 3: 2008 48–59.10.3810/pgm.2008.09.1907CrossRefGoogle ScholarPubMed
Biederman, J., Faraone, S.V.Attention deficit hyperactivity disorder. Lancet. 2005; 366: 237–248.10.1016/S0140-6736(05)66915-2CrossRefGoogle ScholarPubMed
Biederman, J., Faraone, S.V., Spencer, T.J., Mick, E., Monuteaux, M.C., Aleardi, M.Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 67 4: 2006 524–540.10.4088/JCP.v67n0403CrossRefGoogle Scholar
Buitelaar, J.K., Kooij, J.J.S., Ramos-Quiroga, J.A., Dejonckheere, J., Casas, M., van Oene, J.C.et al.Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. Prog Neuro-psychopharmacol Biol Psychiatry. 35 2: 2011 554–560.10.1016/j.pnpbp.2010.12.016CrossRefGoogle ScholarPubMed
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) Canadian ADHD Practice Guidelines, Third Edition. Toronto, ON: CADDRA; 2011.Google Scholar
Capone N, Mc Donnel T. Medication persistence among agents used to treat attention deficit/hyperactivity disorder, diabetes and elevated serum cholesterol. American Psychiatric Association (APA) annual meeting. Toronto; APA; 2006.Google Scholar
Christensen, L., Sasané, R., Hodgkins, P., Harley, C., Tetali, S.Pharmacological treatment patterns among patients with attention deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 26 4: 2010 977–989.10.1185/03007991003673617CrossRefGoogle ScholarPubMed
Corman, C.A., Hallowell, E.M.Positively ADD: real success stories to inspire your dreams. New York: Walker and company; 2006.Google Scholar
Dodson, W.W.Pharmacotherapy of adult ADHD. J Clin Psychol. 61 5: 2005 589–606.10.1002/jclp.20122CrossRefGoogle ScholarPubMed
Gillick, V.West Norfolk and Wisbech Area Health Authority. 1985 3 All ER 402.Google Scholar
Halmøy, A., Fasmer, O.B., Gillberg, C., Haavik, J.Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord. 13 2: 2009 175–187.10.1177/1087054708329777CrossRefGoogle ScholarPubMed
Juniper, E.F., Guyatt, G.H., Ferrie, P.J., King, D.R.Sodium cromoglycate eye drops: regular versus “as needed” use in the treatment of seasonal allergic conjunctivitis. J Allergy Clin Immunology. 94 1: 1994 36–43.10.1016/0091-6749(94)90069-8CrossRefGoogle ScholarPubMed
Kessler, R.C., Lane, M., Stang, P.E., Van Brunt, D.L.The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med. 2009; 39: 137–147.10.1017/S0033291708003309CrossRefGoogle Scholar
Kooij, S.J.J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P.J.et al.European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry. 2010; 10: 67.10.1186/1471-244X-10-67CrossRefGoogle ScholarPubMed
Larriviere, D., Williams, M.A., Rizzo, M., Bonnie, R.J., AAN ethics, law, humanities committee Responding to requests from adult patients for neuroenhancements. Guidance of the ethics, law and humanities committee. Neurology. 2009; 73: 1406–1412.10.1212/WNL.0b013e3181beecfeCrossRefGoogle ScholarPubMed
McBurnett, K., Starr, H.L.OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 12 2: 2011 315–324.10.1517/14656566.2011.546058CrossRefGoogle ScholarPubMed
Murphy, A., Barkley, K.A.Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry. 37 6: 1996 393–401.10.1016/S0010-440X(96)90022-XCrossRefGoogle ScholarPubMed
National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder – diagnosis and management of ADHD in children, young people and adults. NICE Clinical Guideline 72. The British Psychological Society and The Royal College of Psychiatrists, UK; 2008.Google Scholar
Newcorn, J.H., Weiss, M., Stein, M.The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. CNS Spectr. 12 8 Suppl. 12 2007 1–16.10.1017/S1092852900026158CrossRefGoogle ScholarPubMed
Nieuwkerk, P.T., de Boer van der Kolk I.M., Prins, J.M., Locadia, M., Sprangers, M.A.Self-reported adherence is more predictive of virological treatment response among patients with a lower tendency towards socially desirable responding. Antivir Ther. 15 6: 2010 913–916.10.3851/IMP1644CrossRefGoogle ScholarPubMed
Nosé, M., Barbui, C., Gray, B., Tansella, M.Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry. 2003; 183: 197–206.10.1192/bjp.183.3.197CrossRefGoogle ScholarPubMed
Nutt, D.J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K.et al.British Association for Psychopharmacology. Evidence-based guidelines for management of attention deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2006; 21: 10–41.10.1177/0269881106073219CrossRefGoogle ScholarPubMed
Nyström, I., Trygg, T., Woxler, P., Ahlner, J., Kronstrand, R.Quantitation of R-(–)- and S-(+)- amphetamine in hair and blood by gas chromatography-mass spectrometry: an application to compliance monitoring in adult attention deficit hyperactivity disorder treatment. J Anal Toxicol. 2006; 29: 682–688.10.1093/jat/29.7.682CrossRefGoogle Scholar
Osterberg, L., Blaschke, T.Adherence to medication. N Engl J Med. 2005; 353: 487–497.CrossRefGoogle ScholarPubMed
Perwien, A.R., Hall, J., Swensen, A., Swindle, R.Stimulant treatment patterns and compliance in children and adults with newly treated attention deficit/hyperactivity disorder. J Manag Care Pharm. 10 2: 2004 122–129.Google ScholarPubMed
Polanczyk, G., Rohde, L.A.Epidemiology of attention deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 20 4: 2007 386–392.CrossRefGoogle ScholarPubMed
Ramos-Quiroga, J.A., Bosch, R., Castells, X., Valero, S., Nogueira, M., Gómez, N.et al.Effect of switching drug formulations from immediate release to extended release OROS methylphenidate. A chart review of Spanish adults with attention deficit hyperactivity disorder. CNS Drugs. 22 7: 2008 603–611.CrossRefGoogle ScholarPubMed
Retz, W., Rösler, M.The relation of ADHD and violent aggression: what can we learn from epidemiological and genetic studies?. Int J Law Psychiatry. 2009; 32: 235–243.10.1016/j.ijlp.2009.04.006CrossRefGoogle ScholarPubMed
Rösler, M., Casas, M., Konofal, E., Buitelaar, J.Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry. 2010; 11: 684–698.10.3109/15622975.2010.483249CrossRefGoogle ScholarPubMed
Sabaté, E.Adherence to long-term therapies: evidence for action. 2003 World Health Organisation Geneva Available from URL: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf.Google Scholar
Sachdev, P.S., Troller, J.N.How high a dose of stimulant medication in adult attention deficit hyperactivity disorder?. Aust N Z J Psychiatry. 2000; 34: 645–650.10.1080/j.1440-1614.2000.00732.xCrossRefGoogle Scholar
Safren, S.A., Duran, P., Yovel, I., Perlman, C.A., Sprich, S.Medication adherence in psychopharmacologically treated adults with ADHD. J Atten Disord. 10 3: 2007 257–260.10.1177/1087054706292165CrossRefGoogle ScholarPubMed
Secnik, K., Swensen, A., Lage, M.J.Comorbidities and costs of adult patients diagnosed with attention deficit hyperactivity disorder. Pharmacoeconomics. 23 1: 2005 93–102.CrossRefGoogle ScholarPubMed
Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention deficit hyperactivity disorder. J Psychopharmacol 2011, 10.1177/0269881111412095, [Epub ahead of print].10.1177/0269881111412095CrossRefGoogle Scholar
Simon, V., Czobor, P., Bálint, S., Mészáros, A., Bitter, I.Prevalence and correlates of adult attention deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009; 194: 204–211.CrossRefGoogle ScholarPubMed
Swanson, J.Compliance with stimulants for attention deficit/hyperactivity disorder. Issues and approaches for improvement. CNS Drugs. 17 2: 2003 117–131.CrossRefGoogle ScholarPubMed
Torgersen, T., Gjervan, B., Rasmussen, K.Treatment of adult ADHD: is current knowledge useful to clinicians?. Neuropsychiatr Dis Treat. 4 1: 2008 177–186.10.2147/NDT.S1223CrossRefGoogle ScholarPubMed
Upadhyaya, H.Managing attention deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry. 68 suppl. 11: 2007 23–30.CrossRefGoogle ScholarPubMed
Waxmonsky, J.G.Non-stimulant therapies for attention deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol. 6 5: 2005 262–276.Google Scholar
Weisler, R.H., Biederman, J., Spencer, T.J., Wilens, T.E., Faraone, S.V., Chrisman, A.K.et al.Mixed amphetamine salts extended release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 11 8: 2006 625–639.10.1017/S1092852900013687CrossRefGoogle ScholarPubMed
Westra, H.A., Stewart, S.H., Conrad, B.E.Naturalistic manner of benzodiazepine use and cognitive behavioural therapy outcome in panic disorder with agoraphobia. J Anxiety Disord. 2002; 16: 233–246.CrossRefGoogle ScholarPubMed
Wheeler, R.Gillick or Fraser? A plea for consistency over competence in children Gillick and Fraser are not interchangeable. BMJ. 2006; 332: 807.10.1136/bmj.332.7545.807CrossRefGoogle ScholarPubMed
Wilens, T.E.Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 65 suppl. 3: 2004 38–45.Google ScholarPubMed
Wilens, T.E.The nature of the relationship between attention deficit/hyperactivity disorder and substance use. J Clin Psychiatry. 68 suppl. 11: 2007 4–8.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.